In this study, we aimed to investigate the capabilities of six fluoroquinolones to select resistant mutants from Salmonella enterica serotypes Typhimurium and Hadar by determining the MPCs.
The susceptibility to nalidixic acid and six fluoroquinolones (Table 1) of six clinical isolates and one standard strain (ATCC 13311) of Salmonella Typhimurium and eight clinical isolates of Salmonella Hadar was tested by determining the MIC using the agar dilution method according to recommendations of the National Committee for Clinical Laboratory Standards [NCCLS, now known as the Clinical and Laboratory Standards Institute (CLSI)].
3 Clonal relationship of the strains was checked by pulsed-field gel electrophoresis (PFGE) of XbaI-restricted DNA.
To determine the MPCs, a single overnight colony on MuellerHinton agar (MHA) was inoculated in 500 mL of nutrient broth (NB), incubated at 37 C with shaking for 5 h and then adjusted to a turbidity matching that of a 1 McFarland standard. The cells were then harvested by centrifuging at 12 000 g for 30 min at 4 C and resuspending in 3 mL of NB. About 200 mL of this bacterial suspension (containing >10 10 cfu) was spread onto MHA plates containing one of the six fluoroquinolones at serial 2-fold concentrations starting from 0.5· MIC. After 48 h of incubation at 37 C, colonies growing on the fluoroquinolone-containing plate were checked for resistance and identity by subculturing on MacConkey agar containing the same fluoroquinolone at the MIC followed by identification by standard microbiological procedures. The parent was used as a susceptible control on the fluoroquinolone-containing MacConkey plates. MPC was taken as the lowest concentration that inhibited all bacterial growth. The value of C max /MPC was calculated, where C max was the maximum peak serum concentration achievable 1-3 h after an oral dose of a fluoroquinolone. 4, 5 The MICs of the six fluoroquinolones for the strains tested (shown to be clonally unrelated by PFGE) are shown in Table 1 . All were highly susceptible to the six fluoroquinolones tested with MICs as much as 64-fold lower than the susceptible breakpoints recommended by the CLSI 6 or the BSAC. 4 However, when the strains were subcultured in the presence of a fluoroquinolone, resistant strains developed at 1·-32· MIC at a frequency ranging from 10 -11 to 10 -6
. Gemifloxacin could select resistant strains at the highest frequencies (10 -10 -10 -6
), indicating that both Salmonella Typhimurium and Salmonella Hadar could develop fluoroquinolone resistance more readily in the presence of gemifloxacin than any of the other fluoroquinolones.
The MPCs were compared with corresponding MIC and C max values (Table 1 ). In general, results for the standard strain ATCC 13311 were similar to those for clinical isolates of Salmonella Typhimurium except that the MICs and MPCs were 2-to 4-fold lower. The MPC/MIC value of moxifloxacin was the lowest for both Salmonella Typhimurium and Salmonella Hadar, i.e. the MSW was the narrowest, and that of gemifloxacin was the highest, indicating that moxifloxacin could efficiently inhibit the growth of resistant mutants. The C max /MPC of both gemifloxacin and norfloxacin was the lowest while that of ciprofloxacin and levofloxacin was the highest. The MPC of a drug must be below the C max and tissue concentration to effectively restrict growth of resistant mutants clinically. Since the fluoroquinolone concentration in serum is usually lower than that in tissues, an MPC that is lower than C max should also be lower than the concentration achievable in tissues. This is especially important for intracellular organisms such as salmonellae.
Our studies showed that ciprofloxacin was active against salmonellae and was most capable amongst the fluoroquinolones tested to restrict development of resistant strains because of its low MICs and MPCs but high C max /MPC ratio. In contrast, gemifloxacin had the widest MSW and the lowest C max /MPC ratio, indicating that this drug could readily select for resistance. More strains and different Salmonella serotypes should be tested to confirm such findings. Whether these in vitro studies can be reproduced in vivo requires further investigation. The following C max values in mg/L (1-3 h after an oral dose) according to BSAC 4 were used: ciprofloxacin 2.5 (500 mg dose), ofloxacin 4.8 (400 mg dose), levofloxacin 5.5 (500 mg dose), moxifloxacin 3.1 (400 mg dose) and gemifloxacin 1.1 (320 mg dose). The C max value for norfloxacin was not provided by BSAC 4 and was taken as 1.3 mg/L after an oral dose of 400 mg.
